Palvella Therapeutics (PVLA) announced results from the Phase 2 study of QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations were published in the Journal of Vascular Anomalies, JoVA. JoVA, which is the official journal of the International Society for the Study of Vascular Anomalies, ISSVA, is an international peer reviewed journal dedicated to the discovery and report of the scientific investigation, diagnosis, and treatment of congenital and acquired human vascular lesions. “The Phase 2 results highlight QTORIN rapamycin’s potential to be the first targeted therapy for children and adults living with microcystic lymphatic malformations, a serious, rare genetic disease,” said Wes Kaupinen, Founder and Chief Executive Officer of Palvella. “We look forward to further evaluating the potential of QTORIN rapamycin in the ongoing Phase 3 SELVA trial and to expediting this potential first-in-disease therapy to patients.”
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics announces first patients dosed in Phase 2 TOIVA trial
- Wedbush hikes Apple target to high on Street: Morning Buzz
- Progressive, EverQuote upgraded: Wall Street’s top analyst calls
- Palvella Therapeutics initiated with a Buy at H.C. Wainwright
- Twelve option delistings on December 23rd